• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

183.60 -5.33 (-2.82%)
Official Closing Price Updated: 7:00 PM EDT, Mar 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,100,192
Open 188.14
Bid (Size) 182.00 (200)
Ask (Size) 190.98 (100)
Prev. Close 188.93
Today's Range 182.62 - 188.40
52wk Range 182.62 - 212.71
Shares Outstanding N/A
Dividend Yield 0.51%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush
March 18, 2026
As of March 18, 2026, the corporate landscape has undergone a radical transformation. The era of the sprawling global conglomerate, once the gold standard of industrial stability, is rapidly giving way... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Could This International ETF Be One of the Best Investments of 2026? ↗
March 14, 2026
International stocks look attractively valued in an expensive market environment. 
Via The Motley Fool
Topics ETFs

Performance

YTD
-2.6%
-2.6%
1 Month
-10.1%
-10.1%
3 Month
-2.6%
-2.6%
6 Month
-2.6%
-2.6%
1 Year
-2.6%
-2.6%

More News

Read More
News headline image
The 'Sentiment Trap': Why Beating Earnings Is No Longer Enough in the Age of AI Sentiment Analysis
March 13, 2026
Via MarketMinute
Topics Artificial Intelligence Earnings Regulatory Compliance
News headline image
The Billion-Dollar Divide: How "Megadeals" Are Defining a K-Shaped M&A Market in 2026
March 11, 2026
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
March 10, 2026
Via Finterra
Topics Economy Intellectual Property Lawsuit
News headline image
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
March 10, 2026
From AstraZeneca
Via Business Wire
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
March 09, 2026
From AstraZeneca
Via Business Wire
News headline image
The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026
March 05, 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗
March 02, 2026
Via The Motley Fool
Topics Earnings
News headline image
As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗
March 02, 2026
Via MarketBeat
Topics ETFs
News headline image
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound ↗
February 27, 2026
Via MarketBeat
Topics Artificial Intelligence
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
February 26, 2026
Via MarketMinute
Topics Economy Intellectual Property
News headline image
AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange
February 26, 2026
Via MarketMinute
Topics ETFs
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
February 25, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
February 20, 2026
From AstraZeneca
Via Business Wire
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
February 16, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗
February 16, 2026
Via The Motley Fool
Topics ETFs Stocks
News headline image
The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind
February 13, 2026
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
February 13, 2026
From AstraZeneca
Via Business Wire
News headline image
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH ↗
February 12, 2026
Via MarketBeat
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
February 12, 2026
Via Finterra
Topics Economy Intellectual Property
News headline image
The Great Rebound: 2026 Becomes the Year of the Strategic Mega-Deal as M&A Activity Surges
February 11, 2026
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
February 11, 2026
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
February 10, 2026
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
February 10, 2026
Via Finterra
Topics Economy Intellectual Property

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 183.60
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 03/20/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap